CA Patent

CA2669536C — Combinations of ambrisentan and pde5 inhibitors for treating pulmonary arterial hypertension

Assigned to Gilead Sciences Inc · Expires 2016-05-31 · 10y expired

What this patent protects

Use of a therapeutically effective amount of ambrisentan and a therapeutically effective amount of a PDE5 inhibitor for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject.

USPTO Abstract

Use of a therapeutically effective amount of ambrisentan and a therapeutically effective amount of a PDE5 inhibitor for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
CA2669536C
Jurisdiction
CA
Classification
—
Expires
2016-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.